Strategic partnerships ClearPoint Neuro is actively expanding collaboration with academic and research institutions, including a 10-year focused ultrasound development partnership with Sungkyunkwan University in South Korea and epilepsy-focused collaborations. This indicates strong sales opportunities through joint research programs, translational projects, and potential multi-site deployments.

EU regulatory expansion Recent EU MDR certifications for ClearPoint Navigation Software 3.0.2 position the company for broader European market access, enabling sales teams to target European hospitals, neurosurgery centers, and research labs seeking compliant, up-to-date navigation solutions for brain and spine procedures.

Revenue growth signals First-quarter 2026 revenue of 12.1 million, up 43 percent year over year, driven by IRRAflow and robust device demand. This indicates increasing adoption and a growing install base, suggesting upsell opportunities for enhanced navigation software, services, and integrated delivery platforms.

M&A and capacity Acquisition of IRRAS in 2025 signals capacity to broaden product portfolio and accelerate sales through expanded product lines and cross-sell opportunities to existing neuro and spine customers while leveraging combined clinical outcomes.

Global reach Engagement with healthcare and research centers across North America, Europe, Asia, and South America highlights a sizable international addressable market. Sales strategies can target region-specific partnerships, local regulatory strategies, and service networks to accelerate global adoption.